

Resource Summary Report

Generated by [dkNET](#) on Aug 20, 2026

CD279

RRID:AB_394284

Type: Antibody

Proper Citation

BD Biosciences Cat# 551892, RRID:AB_394284

Antibody Information

URL: http://antibodyregistry.org/AB_394284

Proper Citation: BD Biosciences Cat# 551892, RRID:AB_394284

Target Antigen: CD279 (PD-1)

Host Organism: armenian hamster

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: CD279

Description: This monoclonal targets CD279 (PD-1)

Target Organism: mouse

Antibody ID: AB_394284

Vendor: BD Biosciences

Catalog Number: 551892

Record Creation Time: 20250819T234446+0000

Record Last Update: 20250820T061721+0000

Ratings and Alerts

No rating or validation information has been found for CD279.

No alerts have been found for CD279.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 18 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Xie S, et al. (2026) Effector differentiation by stem-like intraepithelial ?? T cells is required for host defense against infection. *Immunity*, 59(3), 577.

Geng H, et al. (2026) Unleashing T cell surveillance for the eradication of quiescent persister tumor cells resistant to neoadjuvant chemotherapy. *Developmental cell*, 61(5), 995.

Wang Y, et al. (2026) AARS1 promotes tumor progression and immune evasion via ATF6 lactylation-mediated tryptophan metabolism in hepatocellular carcinoma. *Cell metabolism*, 38(8), 1702.

Cao C, et al. (2024) CXCR4 orchestrates the TOX-programmed exhausted phenotype of CD8+ T cells via JAK2/STAT3 pathway. *Cell genomics*, 4(10), 100659.

He C, et al. (2024) UFL1 ablation in T cells suppresses PD-1 UFMylation to enhance anti-tumor immunity. *Molecular cell*, 84(6), 1120.

Yang C, et al. (2024) Targeting the immune privilege of tumor-initiating cells to enhance cancer immunotherapy. *Cancer cell*, 42(12), 2064.

Li X, et al. (2024) Deficiency of CBL and CBLB ubiquitin ligases leads to hyper T follicular helper cell responses and lupus by reducing BCL6 degradation. *Immunity*, 57(7), 1603.

Tesfay MZ, et al. (2024) Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade. *Molecular therapy. Oncology*, 32(4), 200913.

Xiao X, et al. (2023) ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy. *Nature communications*, 14(1), 2859.

Dan J, et al. (2023) Oncolytic virus M1 functions as a bifunctional checkpoint inhibitor to enhance the antitumor activity of DC vaccine. *Cell reports. Medicine*, 4(10), 101229.

Ertveldt T, et al. (2023) Targeted ?-Therapy Using ²²⁵Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*, 64(5), 751.

Masle-Farquhar E, et al. (2022) STAT3 gain-of-function mutations connect leukemia with autoimmune disease by pathological NKG2Dhi CD8+ T cell dysregulation and accumulation. *Immunity*, 55(12), 2386.

Wan S, et al. (2021) Costimulation molecules differentially regulate the ERK-Zfp831 axis to shape T follicular helper cell differentiation. *Immunity*, 54(12), 2740.

Sun L, et al. (2021) Transcription factor Ascl2 promotes germinal center B cell responses by directly regulating AID transcription. *Cell reports*, 35(9), 109188.

Du H, et al. (2019) Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells. *Cancer cell*, 35(2), 221.

Ma X, et al. (2019) Cholesterol Induces CD8+ T Cell Exhaustion in the Tumor Microenvironment. *Cell metabolism*, 30(1), 143.

Shen E, et al. (2019) Control of Germinal Center Localization and Lineage Stability of Follicular Regulatory T Cells by the Blimp1 Transcription Factor. *Cell reports*, 29(7), 1848.

Stutz MD, et al. (2018) Is Receptor-Interacting Protein Kinase 3 a Viable Therapeutic Target for Mycobacterium tuberculosis Infection? *Frontiers in immunology*, 9, 1178.